Templeton India Equity Income Fund

Type Open-ended equity (diversified)
Benchmark BSE 200
Min. Investment Rs 5,000
Face Value Rs 10
Entry Load 2.25% (max.)
Exit Load 1.00% (max.)*
Issue Opens March 22, 2006
Issue Closes April 20, 2006

*For redemptions made within 6 months of allotment; 0.50% for amounts less than Rs 5 crore.

Fund Manager:-Dr.J.Mark Mobius

He currently directs the analysts based in Templeton's eleven emerging markets offices and manages the emerging markets portfolios. Dr. Mobius holds Bachelors and Masters Degrees from Boston University, and received his Ph.D. in Economics and Political Science in 1964 from the MIT.

Portfolio

TIEIF is mandated to invest 70%-100% of its assets in equities and equity-linked instruments. Of this, at least 20% will be in large domestic companies; the fund house has defined large companies as those which have a market capitalisation of Rs 13.5 bn and more. Other domestic companies can account for a maximum of 25% of TIEIF's net assets

Opinion

Looking into the past funds and their perfomances and their investment style,I think one can add this to the portfolio.Also investors, who have a flair for equity-oriented investments and are looking to diversify their assets across various economies and currencies, should consider adding the fund to their portfolios.

Reliance petroleum

Period :13 to 20 April 2006
Price:-57-62
Face value -10

The company is entering the capital market with 135 crore shares of 10 Rs each.Reliance industries will subscribe for this IPO for 90 crores at the IPO price.The net susbscription available for the public will be 45 crores approximately.Retail investors have to pay only They can apply for minimum of 100 and maximum of 1600 shares.The IPO money will be used for export oriented refinery at Jamnagar in Gujarat,and for setting up of 900,000 tone per annum polypropelene plant .

Expert Opinion-Subscribe the iPO

With limited additions expected to global refining capacity and an increase in demand for petroleum products forecast for key markets, any current excess of refining capacity is expected to decline further, resulting in greater utilisation of the present refinery capacities.
The introduction of stringent norms and product specifications is expected to result in fewer refineries being able to meet rising demand for such products, particularly since most US and European refineries are thirty years old.
This has provided an opportunity to RPL to capitalise on the imbalance between capacity and demand by rapidly establishing an export-oriented, technologically advanced refinery to harvest a greater share of the rising demand. Further, by commissioning its refinery as early as December 2008, RPL would have a head start of at least two years over other refining giants planning similar greenfield refineries or capacity expansions.

Plethico Pharmaceuticals

Plethico Pharmaceuticals, one of India’s fastest growing pharmaceutical companies in the herbal and nutraceuticals space having global presence, has opened for subscription today through 100% book building offer. The product range include herbal allopathic formulations,consumer healthcare products,food supplements,disposables,hospital consumables,vetenary products

Issue Terms:- Issue price / Floor Price (Rs) -280-300

Issue opens 10-Apr-06

Issue closes 17-Apr-06
Listing on BSE,NSE

Face Value-10

Minimum order quantity-20 shares

Plethico has two fully integrated state-of-the-art manufacturing units located near Indore, which serve as the backbone of the entire operations. These facilities are being upgraded as per stringent norms of UK MHRA.

For the year ended September 2005, it had a total gross block of Rs 115.51 crore (Rs 1.15 billion). It recorded total revenues of Rs 224.48 crore (Rs 2.24 billion) in 2004-05 and Rs 64.21 crore (Rs 642 million) for the quarter ended December 2005, with PAT of Rs 56.13 crore (Rs 561.3 million) and Rs 18.54 crore (Rs 185.4 million), respectively.

According to my opinion one can apply for this IPO for long term perspective.

LOKESH MACHINES